HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PTGX
Protagonist Therapeutics, Inc.
PTGX's fundamentals are strong: revenue more than doubled and its operating margin rose 49 points to 59%. At 28x earnings, it's trading about half its usual 55x. Analysts expect earnings to fall sharply, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PTGX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
PTGX's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PTGX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $62.70 | -53% |
| Current | 28x | $134 | — |
| Fair | 42x | $197 | +47% |
| Expensive | 131x | $618 | +360% |
| Forward | 1,897x | $134 | — |
Historical ranges are pointers, not guarantees.
PTGX's PE is in its fair range at 28x. Analysts expect earnings to fall, which would put today's price at 1897x next year's earnings, in its expensive range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over PTGX on the outlook, with more favorable revenue and profitability expectations.
PTGX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect PTGX's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PTGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.07 | -98% |
| Q3 2026 | $4.72 | +626% |
| Q2 2026 | $1.03 | +41% |
| Q1 2026 | -$1.81 | -332% |
| Q4 2025 | -$2.05 | -148% |
| Q3 2025 | $0.65 | -76% |
| Q2 2025 | $0.73 | -73% |
| Q1 2025 | $0.78 | -69% |
| Q4 2024 | $4.23 | +$5.62 |
PTGX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PTGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $274.4M | +5724% |
| Q2 2026 | $213.5M | +3749% |
| Q1 2026 | $56.4M | +99% |
| Q4 2025 | $7.4M | -96% |
| Q3 2025 | $4.7M | +0.8% |
| Q2 2025 | $5.5M | +33% |
| Q1 2025 | $28.3M | -89% |
| Q4 2024 | $170.6M | +184% |
PTGX's revenue is growing: $274M last quarter, up 5724% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +1065 points |
| Q2 2026 | 74% | +832 points |
| Q1 2026 | -6.5% | +62 points |
| Q4 2025 | -677% | -751 points |
| Q3 2025 | -985% | -99 points |
| Q2 2025 | -758% | +173 points |
| Q1 2025 | -68% | -149 points |
| Q4 2024 | 74% | +36 points |
PTGX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PTGX on cash flow, with more consistent year-over-year improvement.
PTGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.5M | -$21.4M |
| Q2 2026 | $218.9M | +$248.5M |
| Q1 2026 | -$49.2M | -139% |
| Q4 2025 | -$37.1M | -$7.6M |
| Q3 2025 | -$2M | +$26.6M |
| Q2 2025 | -$29.6M | -111% |
| Q1 2025 | $124.8M | +$152.5M |
| Q4 2024 | -$29.5M | -274% |
PTGX has burned cash in almost every quarter: $109M over the past year, up 71% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PTGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PTGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +725K shares |
| 1 year | +12% | +8M shares |
| 3 years | +21% | +12.5M shares |
| 5 years | +49% | +23.7M shares |
| Available history | +177% | +45.8M shares |
PTGX has 72M diluted shares, up 12% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PTGX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -7.0x | Net Cash |
| Q3 2025 | -5.7x | Net Cash |
| Q2 2025 | -6.8x | Net Cash |
| Q1 2025 | -5.0x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
| Q3 2024 | -0.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
PTGX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PTGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.7 | Neutral |
| Stochastic | 31.1 | Neutral |
PTGX's weekly RSI is 53 (neutral) and its Stochastic is 31 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PTGX PE vs Healthcare Sector
| Metric | PTGX | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 10% above |
| PE % | 49 | 29 | 20 pts above |
PTGX is trading at 28x earnings, a 10% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PTGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $138.0 | 2.6% below |
| 20 week MA | $140.9 | 4.6% below |
| 50 week MA | $113.3 | 19% above |
| 100 week MA | $83.7 | 61% above |
| 200 week MA | $55.7 | 141% above |
PTGX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PTGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.00 | $23.8 | +239% |
| 2021 | $23.8 | $34.3 | +44% |
| 2022 | $34.3 | $10.1 | -71% |
| 2023 | $10.1 | $22.9 | +127% |
| 2024 | $22.9 | $39.0 | +70% |
| 2025 | $39.0 | $88.8 | +128% |
| 2026 YTD | $88.8 | $134.4 | +51% |
PTGX has the edge over HIMS on returns for 2026, with the stronger performance.